Digital Public Defence: Ragnhild Johanne Måseide

Cand.med. Ragnhild Johanne Måseide at Institute of Clinical Medicine will be defending the thesis “Moderate haemophilia A and B in the Nordic countries – The MoHem study” for the degree of PhD (Philosophiae Doctor).

Image may contain: Person, Nose, Smile, Glasses, Cheek.

Photo: Ine Eriksen, UiO

The public defence will be held as a video conference over Zoom.

The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.

Click here to participate in the public defence

Download Zoom here

Due to copyright reasons, an electronic copy of the thesis must be ordered from the faculty. In order for the faculty to have time to process the order, it must be received by the faculty no later than 2 days prior to the public defence. Orders received later than 2 days before the defence will not be processed. Inquiries regarding the thesis after the public defence must be addressed to the candidate.

Digital Trial Lecture – time and place

See Digital Trial Lecture.

Adjudication committee

  • First opponent: Professor John Pasi, Queen Mary University of London
  • Second opponent: Adjunct Professor Anna-Elina Lehtinen, HUCH Comprehensive Cancer Center, Meilahti Triangle Hospital
  • Third member and chair of the evaluation committee: Professor II Bjørn Bendz, University of Oslo

Chair of the Defence

Professor Emeritus Stein Arne Evensen, University of Oslo

Principal Supervisor

Professor II Pål André Holme, University of Oslo

Summary

Recurrent joint bleeds lead to progressive arthropathy, which is the main long-term complication for patients with haemophilia. Prophylactic replacement therapy from early age has improved joint health in severe haemophilia (factor VIII/factor IX activity (FVIII/FIX:C) < 1 IU/dL) and is now the standard of care. Patients with moderate haemophilia (1-5 IU/dL) have mainly received episodic treatment, and the prevalence of arthropathy in the group is not well characterised.

The aims of the thesis were to describe current joint health in Nordic patients with moderate haemophilia A (MHA) and B (MHB) in relation to treatment modality, and to explore and compare ultrasound and physical examination to detect early arthropathy. We also explored the role of global coagulation assays to unravel the patients’ bleeding phenotype.

The MoHem study was a cross-sectional, multicentre study covering 145 patients with MHA and MHB in Sweden, Finland, and Norway. Median age was 28 years and 38% were on prophylaxis, started at median 10 years of age. Patients with FVIII/FIX:C ≤ 3 IU/dL and those with MHA had experienced their first joint bleed at a younger age, implying more severe bleeding phenotype. Overall, current joint health was good, but 15% had undergone orthopaedic surgery because of haemophilic arthropathy. FVIII/FIX:C ≤ 3 IU/dL was associated with impaired joint health. Ultrasound clarified the origin of subtle clinical findings and detected subclinical pathology. In a study subgroup, thrombin generation and thromboelastometry distinguished between mild or more severe bleeding phenotypes.

In conclusion, we suggested primary prophylaxis to all patients with FVIII/FIX:C ≤ 3 IU/dL according to similar guidelines as for severe haemophilia. Ultrasound improved joint assessment and should be used regularly in clinical practice to detect early arthropathy. Global coagulation assays were able to discriminate between bleeding phenotypes, which may contribute to personalised treatment.

Additional information

Contact the research support staff.

Published Feb. 2, 2022 4:01 PM - Last modified Feb. 15, 2022 1:46 PM